slotkoers
Korea S.E.
00:00:00 17-06-2024
|
Variatie 5 dagen
|
Verschil t.o.v. 1 jan (%)
|
6.510
KRW
|
0,00%
|
|
-6,60%
|
-33,37%
|
Fiscaal tijdperk: december |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Marktkapitalisatie
1 |
414.066
|
496.808
|
461.602
|
302.627
|
240.562
|
Bedrijfswaarde
1 |
325.300
|
429.482
|
440.442
|
290.738
|
239.883
|
K/w-verhouding
|
-49,9
x
|
-40,9
x
|
-14,5
x
|
-10,1
x
|
-13,3
x
|
Dividendrendement
|
-
|
-
|
-
|
-
|
-
|
Marktkapitalisatie/omzet
|
372
x
|
474
x
|
8.127
x
|
33,2
x
|
49,1
x
|
Bedrijfswaarde/omzet
|
292
x
|
409
x
|
7.755
x
|
31,9
x
|
49
x
|
Bedrijfswaarde/EBITDA
|
-45,3
x
|
-35
x
|
-14,3
x
|
-13,1
x
|
-9,76
x
|
Bedrijfswaarde/FCF
|
-
|
-64.406.290
x
|
-16.019.420
x
|
-14.366.955
x
|
-6.369.765
x
|
FCF Yield
|
-
|
-0%
|
-0%
|
-0%
|
-0%
|
Price to Book
|
4,48
x
|
6,08
x
|
5,31
x
|
5,01
x
|
3,56
x
|
Aantal aandelen (in duizenden)
|
23.460
|
23.545
|
23.917
|
24.018
|
24.623
|
Referentieprijs
2 |
17.650
|
21.100
|
19.300
|
12.600
|
9.770
|
Datum van publicatie
|
19-03-21
|
19-03-21
|
21-03-22
|
21-03-23
|
20-03-24
|
Fiscaal tijdperk: december |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Omzet
1 |
1.113
|
1.049
|
56,8
|
9.118
|
4.899
|
EBITDA
1 |
-7.185
|
-12.285
|
-30.753
|
-22.169
|
-24.578
|
Bedrijfsresultaat (EBIT)
1 |
-8.020
|
-13.303
|
-32.696
|
-25.640
|
-27.832
|
Operationele Marge
|
-720,54%
|
-1.268,26%
|
-57.566,15%
|
-281,22%
|
-568,14%
|
Resultaat voor belastingen (EBT)
1 |
-7.091
|
-12.119
|
-32.253
|
-31.402
|
-19.038
|
Nettowinst (verlies)
1 |
-7.091
|
-12.119
|
-31.637
|
-29.853
|
-17.911
|
Nettomarge
|
-637,15%
|
-1.155,33%
|
-55.701,69%
|
-327,42%
|
-365,62%
|
WPA
2 |
-354,0
|
-516,0
|
-1.329
|
-1.246
|
-734,3
|
Free Cash Flow
|
-
|
-6.668
|
-27.494
|
-20.237
|
-37.660
|
FCF-marge
|
-
|
-635,71%
|
-48.407,44%
|
-221,95%
|
-768,76%
|
Kasstroomconversie (ebitda)
|
-
|
-
|
-
|
-
|
-
|
Kasstroomconversie (nettowinst)
|
-
|
-
|
-
|
-
|
-
|
Dividend per aandeel
|
-
|
-
|
-
|
-
|
-
|
Datum van publicatie
|
19-03-21
|
19-03-21
|
21-03-22
|
21-03-23
|
20-03-24
|
Fiscaal tijdperk: december |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Nettoschuldpositie
1 |
-
|
-
|
-
|
-
|
-
|
Nettokaspositie
1 |
88.766
|
67.327
|
21.161
|
11.889
|
678
|
Hefboom (schuld/ebitda)
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-6.668
|
-27.494
|
-20.237
|
-37.660
|
ROE (netto-inkomsten/eigen vermogen)
|
-
|
-13,8%
|
-37,3%
|
-41,2%
|
-28,7%
|
ROA (netto-inkomsten/totale activa)
|
-
|
-9,3%
|
-20,5%
|
-15%
|
-16,1%
|
Totale activa
1 |
-
|
130.310
|
154.101
|
198.387
|
111.103
|
Nettoactief per aandeel
2 |
3.943
|
3.469
|
3.633
|
2.513
|
2.746
|
Cashflow per aandeel
2 |
123,0
|
146,0
|
288,0
|
755,0
|
421,0
|
Capex
1 |
503
|
867
|
11.845
|
11.185
|
18.336
|
Capex/omzet
|
45,23%
|
82,67%
|
20.854,57%
|
122,68%
|
374,31%
|
Datum van publicatie
|
19-03-21
|
19-03-21
|
21-03-22
|
21-03-23
|
20-03-24
|
|
Vaira. 1 jan.
|
Kapi.
|
---|
| -33,37% | 122 mln. | | +16,42% | 122 mld. | | +19,02% | 113 mld. | | +3,52% | 22,66 mld. | | -11,63% | 16,68 mld. | | -16,50% | 16,61 mld. | | -39,57% | 16,92 mld. | | +2,68% | 13,62 mld. | | +21,16% | 11,04 mld. | | +108,78% | 10,43 mld. |
Biotherapeutische geneesmiddelen
|